24results about How to "Ability to inhibit migration" patented technology

The invention relates to application of recombinant III-type humanized collagen in treatment of cervical cancer, in particular to application of recombinant III-type humanized collagen in preparation of products for preventing and / or inhibiting and / or treating cervical cancer. The amino acid sequence of the recombinant III-type humanized collagen comprises n repetitions of the sequence as shown in SEQ ID NO.1, n is an integer greater than or equal to 1 and preferably is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 20, 24 or 32, and when n is an integer greater than or equal to 2, the repetitions are directly connected. Research data shows that the recombinant III-type humanized collagen can obviously inhibit the proliferation capacity and migration capacity of cervical cancer cells, and help is provided for preparation and wide application of products for preventing and treating cervical cancer and clinical treatment of cervical cancer.

The invention relates to the technical field of milk bottle caps, in particular to a high-strength polyethylene milk bottle cap and a preparation process thereof. The preparation method comprises the following steps: 1, preparing a functional additive: S1, adding polylysine into a nano-montmorillonite dispersion liquid, carrying out intercalation reaction at 60-65 DEG C for 2-3 hours, centrifuging, and drying to obtain modified nano-montmorillonite; s2, in a nitrogen atmosphere, adding caffeic acid into a PBS buffer solution, adding EDC and NHS, and stirring for 15-30 minutes in an ice bath; adding a modified nano montmorillonite-PBS buffer solution, continuously stirring for 24 hours, washing and drying to obtain a functional additive; and 2, mixing the high-density polyethylene, the functional additive, the compatilizer, the aldehyde polyolefin elastomer, palm oil and color master batch, and carrying out melt extrusion and injection molding to obtain the high-strength polyethylene milk bottle cap. In the scheme, the prepared high-strength polyethylene milk bottle cap has excellent mechanical strength and oxygen barrier property.

The invention provides application of hypericin nanoparticles subjected to photodynamic treatment in preparation of a medicine for inhibiting liver cancer cells. The hypericin nanoparticles (HC-NPs) are formed by wrapping a traditional Chinese medicine monomer hypericin (HC) with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000). The hypericin nano-particles provided by the invention have an obvious inhibition effect on liver cancer cells under a specific illumination condition, so that the expression of the gene SERPINE1 is up-regulated in a time-dependent and dose-dependent manner. The gene participates in regulation of biological behaviors of liver cancer, and provides a new view angle for treatment of liver cancer.

The invention discloses an application of cinobufagin in preparation of a medicine for inhibiting bone metastasis of lung cancer. It is proved for the first time that 1) in-vitro cell experiments prove that cinobufagin can effectively inhibit proliferation and migration ability of lung cancer bone metastasis cells and promote cell apoptosis; 2) a mouse left ventricular injection bone metastasis model and a tibia injection model show that cinobufagin can significantly inhibit the development of lung cancer bone metastasis and osteolytic bone injury; (3) the specific regulation and control mechanism of cinobufagin for inhibiting bone metastasis of lung cancer is explored, and it is found through combined analysis of IP-MS proteomics and LiP-SMap proteomics that cinobufagin may target pyruvate carboxylase to play the function of cinobufagin; and 4) further verifying that cinobufagin can be combined with PC to inhibit bone metastasis of lung cancer through a drug affinity reactive target stability experiment and a heat transfer experiment. The research provides a new target spot and a treatment strategy for inhibiting bone metastasis of lung cancer.

The invention discloses an application of a treatment target in a product for inhibiting transfer and proliferation of kidney cancer cells. The nucleotide sequence of the C8orf76 treatment target is as shown in SEQ ID NO. 1; the expression protein of the C8orf76 therapeutic target spot is a C8orf76 protein; the amino acid sequence of the C8orf76 protein is as shown in SEQ ID NO. 2. The invention discloses C8orf76 with a nucleotide sequence as shown in SEQ ID NO.1 and C8orf76 protein with an amino acid sequence as shown in SEQ ID NO.2, and discloses application of the C8orf76 protein in preparation of products for inhibiting transfer and proliferation of kidney cancer cells, and the C8orf76 protein is a new target for diagnosis and gene therapy of ccRCC.

The invention discloses a small molecule compound TII-C2 and an application thereof in preparation of a medicine for treating TRADD related autoimmune diseases. According to the present invention, the combination of the small molecule compound TII-C2 and TRADD can destroy the combination of TRADD and TRAF2, significantly inhibit the activation of a TNFR1 downstream signal channel, and inhibit the abnormal proliferation of fibroblast-like synovial cells, such that the clinical manifestation of an arthritis mouse model is improved, and the important reference is provided for the treatment of rheumatoid arthritis and TRADD-related autoimmune diseases; good application prospects are realized.

The invention discloses DUSP23 targeted siRNA and application thereof, and belongs to the technical field of molecular biotechnology and genetic engineering. By researching the expression level of DUSP23 in liver cancer tissues, an action target of the DUSP23 gene is provided for treatment of liver cancer; the invention provides siRNA for inhibiting expression of a human DUSP23 gene and protein and application of the siRNA. The nucleotide sequence of the siRNA is shown as SEQ ID NO.5-SEQ ID NO.6. The invention further provides a preparation method of the siRNA. By transfecting the siRNA in a hepatoma carcinoma cell line, DUSP23 gene and protein expression can be regulated and interfered, cell proliferation and migration ability can be inhibited, cell cycle G0 / G1 phase arrest and cell apoptosis can be induced, and the siRNA has remarkable tumor inhibition activity on transplanted tumor in nude mice of hepatoma carcinoma cells.

This invention discloses the application of a branched-chain amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (valine, isoleucine, and leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the transcriptional expression of its target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver metastasis effect. This invention provides a novel dietary intervention strategy and drug target for the treatment of liver metastases of tumors.

The invention discloses application of an acer palmatum 'Jinling Huangfeng' extract in preparation of a medicine for preventing and treating breast cancer, and belongs to the technical field of natural product extraction. The invention further discloses an extraction method of the acer palmatum 'Jinling Huangfeng' extract and a separation method of active ingredients of the acer palmatum 'Jinling Huangfeng' extract. Scratch repair experiments directly prove that the acer palmatum 'Jinling Huangfeng' extract can significantly inhibit the migration ability of highly metastatic breast cancer cells MDA-MB-231. The separation method of the active components of the acer palmatum 'Jinling Huangfeng' extract is closely linked with anti-breast cancer metastasis activity screening, so that the experimental process has definite pharmacological guidance quality, the efficiency and success rate of finding the active components are greatly improved, and a high-value candidate resource is provided for developing anti-metastasis drugs.

This invention discloses a liposome, a drug-loaded liposome, its preparation method, and its applications. The liposome comprises a liposome backbone and a targeting ligand; wherein the liposome backbone comprises the following components: phospholipids, cholesterol, cationic lipids, and PEGylated phospholipids; the cationic lipids are (2,3-dioleoyl-propyl)-trimethylammonium chloride and / or 1,2-dioleoyl-3-trimethylammonium propane; and the targeting ligands are sodium hyaluronate and / or hyaluronic acid. This liposome possesses excellent basic properties and excellent targeting ability; after encapsulating the active pharmaceutical ingredients (doxacin hydrochloride and berberine hydrochloride), its targeting ability can be further enhanced in practical applications, thereby increasing its efficacy.

The present invention discloses the application of Cdc37 (cell division cycle protein 37) as a target for the prevention and treatment of rheumatoid arthritis. The present invention also discloses the application of an inhibitor of the Cdc37 gene in the preparation of a drug for the prevention or treatment of rheumatoid arthritis. The inhibitor of the Cdc37 gene reduces the expression of Cdc37 in FLS, thereby inhibiting the proliferation of FLS, and weakening the inflammatory response and migration ability of FLS, thereby achieving the effect of preventing / treating RA. The present invention provides the application of Cdc37 as a target for the prevention and treatment of rheumatoid arthritis. It is found for the first time that Cdc37 is highly expressed in RA synovial tissue, and inhibiting Cdc37 can significantly inhibit the proliferation of FLS, and weaken the inflammatory response and migration ability of FLS. Cdc37 has great potential as a specific diagnostic and therapeutic target for RA patients, and provides a theoretical basis for the development of new anti-RA drugs.

This invention belongs to the field of pharmaceutical technology, specifically relating to a novel use of berberine hydrochloride and a pharmaceutical composition. Berberine hydrochloride has the structure shown below, and it significantly inhibits the expression of HMGB3 in triple-negative breast cancer cells, significantly inhibits the proliferation, colony formation, invasion, and migration of triple-negative breast cancer cells, and promotes apoptosis in triple-negative breast cancer cells. Therefore, berberine hydrochloride can be used to prepare drugs for the prevention and / or treatment of triple-negative breast cancer. Furthermore, berberine hydrochloride can enhance the drug sensitivity of cisplatin; the combined use of berberine hydrochloride and cisplatin has a strong synergistic effect in the treatment of triple-negative breast cancer, providing more treatment options for clinical treatment of triple-negative breast cancer.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The invention discloses an application of a novel peptide UPCP in preparation of a medicine for treating and / or preventing psoriasis. Belongs to the technical field of biological medicine. The application discloses the treatment effect of the novel peptide UPCP on psoriasis for the first time, and researches find that the novel peptide UPCP can effectively relieve symptoms of a psoriasis model induced by LSP, TNF alpha and M2 in an in-vitro cell experiment, significantly down-regulate the expression level of psoriasis cell markers, significantly reduce the transcriptional level of psoriasis-related inflammatory factors, and improve the psoriasis treatment effect. The condition of excessive proliferation of HaCaT cells is effectively reduced. In in-vivo experiments, psoriasis symptoms such as skin desquamation, hyperplasia, erythema, thickening and splenomegaly of an imiquimod-induced psoriasis mouse model can be effectively relieved, the effect of treating psoriasis is achieved, and a new theoretical basis and intervention means are provided for clinical treatment of psoriasis.

The invention provides a photopolymer composition for a holographic grating, the holographic grating and a holographic display system. The photopolymer composition is prepared from the following components in percentage by mass: 30 to 65 percent of polymeric monomer containing an epoxy group, 0.5 to 5 percent of epoxy modified dye, 0.5 to 5 percent of epoxy modified photoinitiator, 30 to 65 percent of film-forming agent and 0.1 to 5 percent of optional additive, the epoxy modified photoinitiator comprises the following raw materials: first epoxy resin containing at least one epoxy group and a micromolecular photoinitiator containing at least one hydroxyl group. According to the photopolymer composition, the first epoxy resin and the small molecular initiator are connected through the ring-opening reaction to form the modified photoinitiator with an epoxy polymer side chain with large molecular weight, and the modified photoinitiator is easily dispersed in a non-solvent organic system, so that the solubility and dispersity of the modified photoinitiator in a photopolymer material are improved.

The invention discloses an MSANTD2 gene as well as an RNAi lentivirus interference system and application thereof, and relates to the technical field of biological medicines. According to the application of the MSANTD2 gene in preparation of the medicine for treating the colorectal cancer, the treatment of the colorectal cancer refers to inhibition of proliferation activity and migration invasion ability of colorectal cancer cells. The MSANTD2 gene is used as a target spot to inhibit MSANTD2 protein expression in colorectal cancer cells, an RNAi lentivirus interference system of the MSANTD2 gene is constructed, a medicine for treating colorectal cancer is prepared, and a kit for disease diagnosis of colorectal cancer high-expression MSANTD2 gene / protein is prepared. The invention provides a new strategy and direction for treatment of colorectal cancer, has extremely high clinical application value, and is expected to bring a better treatment effect for patients with colorectal cancer.

The invention belongs to the technical field of biological medicine, discloses application of an anti-tumor nano-drug with a radiotherapy sensitization effect, and particularly discloses application of azodiisobutyronitrile in preparation of a sensitizer, preparation of an anti-tumor drug with a sensitization effect or preparation of an anti-tumor drug carrier with a sensitization effect. According to the invention, azobisisobutyronitrile is used for preparing the sensitizer (X-ray radiotherapy sensitizer) for the first time, and Pluronic F127 (F127) is used for encapsulating azobisisobutyronitrile to obtain the radiotherapy sensitizer AIBN-coated F127. After X-ray irradiation, AIBN (at) F127 taken by tumor cells is activated, azo free radicals are generated in situ, and a strong anti-cancer effect is achieved. The TNBC cells can be effectively killed, so that the stronger anti-tumor immunocompetence is mobilized.

The invention belongs to the technical field of biological medicine, and particularly relates to a construction method and application of a hepatoma cell line for overexpressing or knocking down an S100A16 gene, the hepatoma cell line for overexpressing or knocking down the S100A16 gene is constructed by adopting a lentivirus construction and lentivirus infection method, and the hepatoma cell line for overexpressing or knocking down the S100A16 gene is applied to preparation of drugs for inhibiting proliferation, invasion and migration of hepatocellular carcinoma. The invention verifies that a hepatoma cell line knocking down the S100A16 gene can promote apoptosis of hepatoma cells, the proliferation and migration capabilities of the hepatoma cells are obviously inhibited, and the proliferation, invasion and migration of the hepatoma cells are obviously promoted by the hepatoma cells overexpressing the S100A16 gene, so that the S100A16 can be used as a new drug target and can be used for preparing drugs for treating liver cancer diseases. The S100A16 gene plays an important role in preparation of drugs for inhibiting proliferation, invasion and migration of hepatocellular carcinoma.

The invention provides regulation and control application in liver cancer cells based on BHMT and PPAR gamma methylation, and relates to the technical field of biological medicines. The invention verifies that the content of the BHMT in liver cancer tissues is obviously reduced, and the content of the BHMT in cancer tissues of MVI patients is obviously reduced, which indicates that the BHMT can be used as a biomarker for predicting and evaluating the MVI occurrence probability of the liver cancer patients. The invention also verifies that the overexpressed BHMT can significantly inhibit the proliferation and transfer ability of hepatoma carcinoma cells in vivo, and verifies that the knockout of BHMT leads to enrichment of PPAR signal pathways in hepatoma carcinoma cells and the expression of PPAR gamma is significantly increased by researching the action relationship between BHMT and PPAR gamma signal pathways; the expression level of SAM can be remarkably improved by overexpressing BHMT, so that the methylation level of a PPAR gamma promoter is up-regulated, and the purpose of inhibiting PPAR gamma expression is achieved. The results show that in the development stage of liver cancer after formation, the drug over-expressing BHMT can inhibit proliferation and migration of liver cancer cells by inhibiting the expression level of PPAR gamma. The invention provides a new treatment thought and method for treating liver cancer and predicting postoperative metastasis and recurrence.

The invention relates to the technical field of biology, in particular to application of a CDH18 gene serving as a target spot to screening of drugs for preventing or treating cervical cancer, the drugs take the CDH18 gene as the target spot, expression of the CDH18 gene is inhibited or silenced, the proliferation and migration capacity of cervical cancer cells can be enhanced by regulating and controlling a Wnt pathway through overexpression of the CDH18 gene, and the drugs for preventing or treating cervical cancer can be used for preventing or treating cervical cancer. The down-regulation of the CDH18 gene inhibits the expression of beta-catenin, the knock-down of the CDH18 gene can inhibit the proliferation and migration ability of cervical cancer cells by regulating and controlling a Wnt signal pathway, the kaempferide has a certain potential anti-tumor activity effect in the cervical cancer cells, the kaempferide can induce the apoptosis of SiHa and HeLa cells of cervical cancer, and the kaempferide can inhibit the proliferation and migration ability of the cervical cancer cells. Experiments show that the kaempferide inhibits the expression level of Wnt signal pathway related molecules by reducing the expression level of CDH18, further promotes apoptosis of cervical cancer cells and inhibits proliferation and migration of the cervical cancer cells.

The invention relates to the technical field of oncology and drug development, in particular to application of tea polyphenol in prevention and treatment of triple-negative breast cancer, and particularly discloses application of tea polyphenol in any one or more of the following scenes: a1) inhibiting proliferation of triple-negative breast cancer cells or preparing a product for inhibiting proliferation of triple-negative breast cancer cells, a2) inhibiting proliferation of triple-negative breast cancer cells, a3) inhibiting proliferation of triple-negative breast cancer cells, a4) inhibiting proliferation of triple-negative breast cancer cells and a4) inhibiting proliferation of triple-negative breast cancer cells; a2) inhibiting migration and invasion of triple negative breast cancer cells or preparing a product for inhibiting migration and invasion of triple negative breast cancer cells; a3) inhibiting the survival of the triple-negative breast cancer or preparing a product for inhibiting the survival of the triple-negative breast cancer; a4) preparing a product for preventing and / or treating triple negative breast cancer; and a5) detecting and monitoring the regulation effect of the tea polyphenol on the miRNA expression of the triple negative breast cancer cells. The tea polyphenol inhibits unlimited rapid proliferation, invasion and migration of triple negative breast cancer cells by influencing the cell cycle process, inducing cell apoptosis, interfering cytoskeleton recombination and inhibiting cell adhesion, and improves the prognosis and survival rate of triple negative breast cancer patients.

The invention relates to the technical field of medicinal chemistry, in particular to application of mebendazole in preparation of a medicine with an osteosarcoma prevention and / or treatment effect. The invention provides a brand new application of mebendazole. Researches show that mebendazole can significantly inhibit proliferation, invasion and migration capabilities of osteosarcoma cells in vitro, can inhibit in-situ growth of osteosarcoma cells in vivo, and significantly reduces the number and area of pulmonary metastatic nodules; therefore, mebendazole serving as an active ingredient is used for preparing the medicine with the effect of preventing and / or treating osteosarcoma, especially the medicine with the effect of preventing and / or treating metastasis, and has a wide application prospect.

The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.

The invention belongs to the technical field of biological medicines, and discloses a mulberry leaf deoxynojirimycin pharmaceutical composition for treating cancers. The pharmaceutical composition comprises an IFITM3 protein monoclonal antibody and mulberry leaf deoxynojirimycin, the amino acid sequence of an antibody light chain variable region of the IFITM3 protein monoclonal antibody is as shown in SEQ ID NO.3, and the amino acid sequence of an antibody heavy chain variable region of the IFITM3 protein monoclonal antibody is as shown in SEQ ID NO.4. In the monoclonal antibody and mulberry leaf deoxynojirimycin composition provided by the invention, the IFITM3 protein monoclonal antibody can be produced in batches, can be specifically combined with human IFITM3 protein, and has the effect of reducing the activity of gastric cancer cells; the mulberry leaf deoxynojirimycin is simple in extraction step and contains few impurities; after the IFITM3 protein monoclonal antibody and the mulberry leaf deoxynojirimycin are used together, the growth and migration ability of gastric cancer cells can be effectively inhibited within a short time, the medicine can be positioned to gastric cancer tissues after entering a human body, the gastric cancer can be treated and relapse can be prevented by inhibiting self-renewal and migration of the cancer cells, and the medicine has a relatively good medical application prospect.